PTEN and cancer: Notably, compared to participants with P/LP germline PTEN variants, carriers of PTEN VUS had a lower prevalence of cancer diagnoses (OR, 0.27; 95% CI 0.14–0.53; P<0.001), and an older age at first cancer diagnosis (61 years versus 48 years, P<0.001) (Supplementary Table 1 and Supplementary Fig. 1A).